Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale.
MND
PLS
PLSFRS
PUMND
clinical trials
clinimetric scale
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
20
09
2019
revised:
07
11
2019
accepted:
19
11
2019
pubmed:
24
11
2019
medline:
14
4
2020
entrez:
24
11
2019
Statut:
ppublish
Résumé
Our research aim was to develop a novel clinimetric scale sensitive enough to detect disease progression in primary lateral sclerosis (PLS). A prototype of the PLS Functional Rating Scale (PLSFRS) was generated. Seventy-seven participants with PLS were enrolled and evaluated at 21 sites that comprised the PLSFRS study group. Participants were assessed using the PLSFRS, Neuro-Quality of Life (QoL), Schwab-England Activities of Daily Living (ADL), and the Clinical Global Impression of Change scales. Participants completed telephone assessments at 12, 24, and 48 weeks after enrollment. The PLSFRS demonstrated internal consistency as well as intrarater, interrater, telephone test-retest reliability, and construct validity. Significant changes in disease progression were detected at 6 and 12 months; changes measured by the PLSFRS vs the ALSFRS-R were significantly higher. The PLSFRS is a valid tool to assess the natural history of PLS in a shorter study period.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-172Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
D'Amico E, Pasmantier M, Lee YW, Weimer L, Mitsumoto H. Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle Nerve. 2013;47:28-32.
Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology. 2009;72:1948-1952.
Mitsumoto H, Nagy PL, Gennings C, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015;1:e3.
Murphy MJ, Grace GM, Tartaglia MC, et al. Cerebral haemodynamic changes accompanying cognitive impairment in primary lateral sclerosis. Amyotroph Lateral Scler. 2008;9:359-368.
Kolind S, Sharma R, Knight S, Johansen-Berg H, Talbot K, Turner MR. Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:562-573.
Paganoni S, Alshikho MJ, Zurcher NR, et al. Imaging of glia activation in people with primary lateral sclerosis. Neuroimage Clin. 2018;17:347-353.
Muller HP, Gorges M, Kassubek R, Dorst J, Ludolph AC, Kassubek J. Identical patterns of cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: a tract of interest-based MRI study. Neuroimage Clin. 2018;18:762-769.
Clark MG, Smallwood Shoukry R, Huang CJ, Danielian LE, Bageac D, Floeter MK. Loss of functional connectivity is an early imaging marker in primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:562-569.
Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:133-145.
ALS CNTF Treatment Study (ACTS) phase I-II study group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53:141-147.
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13-21.
Gordon PH, Miller RG, ALSFRS-R MDH. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):90-93.
Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127-1138.
Writing Group, Edaravone (MCI 186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512.
Mitsumoto H, Factor-Litvak P, Andrews H, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:192-203.
Thompson JL, Levy G. ALS issues in clinical trials. Missing data. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):48-51.
Gershon RC, Lai JS, Bode R, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21:475-486.
Schwab RS, England AC. Projection techniques for evaluating surgery in Parkinson's Disease. Third Symposium on Parkinson's Disease, Royal College of Surgeons. Edinburgh: Churchill Livingstone; 1969:152-159.
Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology. 1986;36:937-941.
Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:50-54.
Kaufmann P, Levy G, Montes J, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8:42-46.
Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653.
McElhiney M, Rabkin JG, Goetz R, et al. Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:398-405.
Hashizume A, Katsuno M, Banno H, et al. Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. J Neurol. 2012;259:712-719.
Hijikata Y, Katsuno M, Suzuki K, et al. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: protocol for a randomized, double-blind, placebo-controlled trial. JMIR Res Protoc. 2018;7:e69.